ProQR Therapeutics N.V.
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
PRQR | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL0010872495
- LEI:
- Country:
- United States of America
- Address:
- ZERNIKEDREEF 9, LEIDEN
- Website:
- https://www.proqr.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ProQR Therapeutics N.V. is a biotechnology company dedicated to the discovery and development of RNA therapies for severe rare and common genetic disorders. The company's core focus is its proprietary Axiomer® RNA-editing technology platform. This platform is designed to make targeted edits to RNA by recruiting the body's own ADAR (Adenosine Deaminase Acting on RNA) enzymes, representing a novel approach to treating diseases with high unmet medical needs. ProQR advances its technology through in-house research and development as well as strategic partnerships, including a major collaboration with Eli Lilly and Company to discover, develop, and commercialize new medicines.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ProQR Therapeutics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ProQR Therapeutics N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ProQR Therapeutics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
